April 2021 tender notification

Medicines

Tender Closed

PHARMAC is pleased to provide the latest tender results.

Tender results

PHARMAC has resolved to award tenders for Principal Supply Status for some products included in the 2020/21 Invitation to Tender, dated 2 November 2020 and has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2019/20 Invitation to Tender dated 1 November 2019.

Some of the pharmaceuticals that will be delisted when the period of Principal Supply Status, Sole Subsidised Supply Status, Hospital Supply Status (as relevant) commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to PHARMAC, the Pharmacy Guild and the NZULM by:

  • For new listings, by 4pm on 12 May 2021 or the 5th of the month prior to listing, whichever is earlier
  • For price changes, by 4pm on the 12th of the month prior to the date of subsidy change

PHARMAC cannot list a product (and pharmacies cannot claim) without this information. 

More information about this process and NOPC forms can be found on our website.

Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link)  and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link).

Pharmacodes and CTPP codes must be provided to PHARMAC by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest).

PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.

2020/21 Tender – Principal Supply Status applies until 30 June 2024

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name

Presentation;
Pack size and type

Current
pack price

New
pack price

Principal Supply brand
(Supplier)

Date of subsidy change

Principal Supply date

Diclofenac sodium

Eye drops 0.1%;

5 ml OP dropper bottle

$13.80

$8.80

Voltaren Ophtha

(Novartis)

1 June 2021

1 November 2021

Dorzolamide with timolol

Eye drops 2% with timolol 0.5%;

5 ml OP dropper bottle

$2.87

$2.73

Dortimopt

(Mylan)

1 July 2021

1 December 2021

Filgrastim

Inj 300 mcg per 0.5 ml prefilled syringe;

10 prefilled syringe pack

$96.22

$96.22

Nivestim

(Pfizer)

1 July 2021

1 December 2021

Filgrastim

Inj 480 mcg per 0.5 ml prefilled syringe;

10 prefilled syringe pack

$161.50

$148.58

Nivestim

(Pfizer)

1 July 2021

1 December 2021

Ornidazole

Tab 500 mg,

10 tablet blister pack

$32.95

$36.16

Arrow-Ornidazole

(Teva)

1 July 2021

1 December 2021

2. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical name

Presentation;
Pack size and type

Current
pack price

New
pack price

Principal Supply brand (Supplier)

Date of subsidy change

Principal Supply date

Brand (Supplier) affected by delisting)

Bisacodyl

Tab 5 mg;

 200 tablet blister pack

$5.99

$5.80

Pharmacy Health

(PSM Healthcare)

1 November 2021

1 April 2022

Lax-Tab

(AFT)

Lopinavir with ritonavir

Tab 100 mg with ritonavir 25 mg;

60 tablet blister pack

$183.75

$150.00

Lopinavir/Ritonavir Mylan

 (Mylan)

1 September 2021

1 February 2022

Kaletra

(AbbVie)

Lopinavir with ritonavir

Tab 200 mg with ritonavir 50 mg;

120 tablet blister pack

$463.00

$295.00

Lopinavir/Ritonavir Mylan

 (Mylan)

1 September 2021

1 February 2022

Kaletra

(AbbVie)

Rivastigmine

Patch 4.6 mg per 24 hour;

30 patch pack

$48.75

$38.00

Rivastigmine Patch BNM 5 (Boucher and Muir)

1 September 2021

1 February 2022

Generic Partners

(Generic Partners)

Rivastigmine

Patch 9.5 mg per 24 hours;

30 patch pack

$48.75

$38.00

Rivastigmine Patch BNM 10 (Boucher and Muir)

1 September 2021

1 February 2022

Generic Partners

(Generic Partners)

Varenicline tartrate

Tab 0.5 mg x 11 and 1 mg x 42;

53 tablet blister pack

$25.64

$16.67

Varenicline Pfizer

(Pfizer)

1 August 2021

1 January 2022

Champix

(Pfizer)1

Varenicline tartrate

Tab 1 mg;

56 tablet blister pack

$27.10

$17.62

Varenicline Pfizer

(Pfizer)

1 August 2021

1 January 2022

Champix

(Pfizer)1

1 Champix will be temporarily listed from 1 May 2021.

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule      

3. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name

Presentation;
Pack size and type

Current
pack price

New
pack price

Principal Supply brand
(Supplier)

DV
Limit

Listing date

Principal Supply Status date

Diclofenac sodium

Eye drops 0.1%;

5 ml dropper bottle

$13.80

$8.80

Voltaren Ophtha

(Novartis)

5%

1 June 2021

1 November 2021

Dorzolamide with timolol

Eye drops 2% with timolol 0.5%,

5 ml dropper bottle

$2.87

$2.73

Dortimopt

(Mylan)

5%

1 July 2021

1 December 2021

Filgrastim

Inj 300 mcg per 0.5 ml prefilled syringe;

10 prefilled syringe pack

$96.22

$96.22

Nivestim

(Pfizer)

5%

1 July 2021

1 December 2021

Filgrastim

Inj 480 mcg per 0.5 ml prefilled syringe;

10 prefilled syringe pack

$161.50

$148.58

Nivestim

(Pfizer)

5%

1 July 2021

1 December 2021

Ornidazole

Tab 500 mg,

10 tablet blister pack

$32.95

$36.16

Arrow-Ornidazole

(Teva)

5%

1 July 2021

1 December 2021

4. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical name

Presentation;
Pack size and type

Current pack price

New pack price

Principal Supply brand (Supplier)

DV Limit

Listing date

Principal Supply Status date

Brand (Supplier) affected by delisting

Bisacodyl

Tab 5 mg;

200 tablet blister pack

$5.99

$5.80

Pharmacy Health (PSM Healthcare)

5%

1 November 2021

1 April 2022

Lax-Tab

 (AFT)

Lopinavir with ritonavir

Tab 100 mg with ritonavir 25 mg;

60 tablet blister pack

$183.75

$150.00

Lopinavir/Ritonavir Mylan (Mylan)

5%

1 September 2021

1 February 2022

Kaletra

(AbbVie)

Lopinavir with ritonavir

Tab 200 mg with ritonavir 50 mg;

120 tablet blister pack

$463.00

$295.00

Lopinavir/Ritonavir Mylan (Mylan)

5%

1 September 2021

1 February 2022

Kaletra

(AbbVie)

Rivastigmine

Patch 4.6 mg per 24 hour;

30 patch pack

$48.75

$38.00

Rivastigmine Patch BNM 5 (Boucher and Muir)

5%

1 September 2021

1 February 2022

Generic Partners

(Generic Partners)

Rivastigmine

Patch 9.5 mg per 24 hours;

30 patch pack

$48.75

$38.00

Rivastigmine Patch BNM 10 (Boucher and Muir)

5%

1 September 2021

1 February 2022

Generic Partners

(Generic Partners)

2019/20 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2023

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

5. Tenders awarded to pharmaceuticals where no brand is listed.

The decisions were as follows:

Chemical name

Presentation;
Pack size and type

New
pack price

Sole supply brand
(Supplier)

Listing date

Sole Subsidised Supply date

Tacrolimus2

Oint 0.1%, 30 g OP tube

$33.00

Zematop (Douglas)

1 October 2021

1 March 2022

2 Special Authority criteria will apply as consulted on 11 August 2020.

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

6. Tenders awarded to pharmaceuticals where no brand is listed.

The decisions were as follows:

Chemical name

Presentation;
Pack size and type

New
pack price

Hospital supply brand
(Supplier)

DV
Limit

Listing date

Hospital Supply Status date

Tacrolimus 3

Oint 0.1%, 30 g tube

$33.00

Zematop (Douglas)

1%

1 October 2021

1 March 2022

3 Hospital restriction criteria will apply as consulted on 11 August 2020.

Tender declines - Products where no tender is to be awarded for Principal Supply Status, Sole Subsidised Supply Status or Hospital Supply Status

PHARMAC has resolved not to award tenders for Principal Supply Status, Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in:

  • the 2020/21 Invitation to Tender, dated 2 November 2020
  • the 2019/20 Invitation to Tender, dated 1 November 2019
  • the 2018/19 Invitation to Tender, dated 1 November 2018

2020/21 Invitation to Tender

Chemical name

Line item

Atovaquone with proguanil hydrochloride

Tab 62.5 mg with proguanil hydrochloride 25 mg

Atovaquone with proguanil hydrochloride

Tab 250 mg with proguanil hydrochloride 100 mg

Budesonide

Rectal enema 2 – 4 mg

Calcium carbonate

Orai liq

Calcium carbonate

Tab eff 0.875 – 175 g (0.5 g – 1 g elemental)

Calcium gluconate

Gel 2.5%

Captopril

Oral liq 5 mg per ml

Crotamiton

Lotn 10%

Dantrolene sodium

Cap 25 mg

Dantrolene sodium

Cap 50 mg

Dantrolene sodium

Inj

Fexofenadine hydrochloride

Tab 60 mg

Fexofenadine hydrochloride

Tab 120 mg

Fexofenadine hydrochloride

Tab 180 mg

Glyceryl trinitrate

Inj 1 mg per ml, 5 ml

Glyceryl trinitrate

Inj 1 mg per ml, 50 ml

Linezolid

Oral liq 20 mg per ml

Methylprednisolone

Tab 4 mg

Methylprednisolone

Tab 100 mg

Methylprednisolone aceponate

Crm 0.1%

Methylprednisolone acetate

Inj 40 mg per ml, 1 ml

Methylprednisolone sodium

Inj 40 mg

Methylprednisolone sodium

Inj 125 mg

Methylprednisolone sodium

Inj 500 mg

Methylprednisolone sodium

Inj 1 g

Metoprolol tartrate

Tab long-acting 200 mg

Promethazine hydrochloride

Inj 25 mg per ml, 2 ml

Ticarcillin with clavulanic acid

Inj 3 g with clavulanic acid 0.1 mg

Tropisetron

Inj 1 mg per ml, 2 ml

Tropisetron

Inj 1 mg per ml, 5 ml

2019/20 Invitation to Tender

Chemical name

Line item

Clotrimazole

Crm 1%

Irbesartan

Tab/cap 75 mg

Irbesartan

Tab/cap 150 mg

Irbesartan

Tab/cap 300 mg

Irbesartan with hydrochlorothiazide

Tab/cap 150 mg with hydrochlorothiazide 12.5 mg

Irbesartan with hydrochlorothiazide

Tab/cap 300 mg with hydrochlorothiazide 12.5 mg

Irbesartan with hydrochlorothiazide

Tab/cap 300 mg with hydrochlorothiazide 25 mg

Sodium alginate with sodium bicarbonate and calcium carbonate

Oral liq

Tadalafil

Tab/cap 2.5 mg

Tadalafil

Tab/cap 5 mg

Tadalafil

Tab/cap 10 mg

Tadalafil

Tab/cap 20 mg

2018/19 Invitation to Tender

Chemical name

Line item

Cefalexin

Cap 500 mg

Tenoxicam

Inj 20 mg

For products included in the 2018/19, 2019/20 or 2020/21 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification, please contact PHARMAC on 0800 66 00 50.